Involvement of Inflammation in Pathogenesis of Arterial and Venous Thromboembolic Disease

Dear Colleagues,

Inflammation represents the basic pathogenetic mechanism of atherosclerosis. Inflammation mediates all stages of the disease, from initiation to the thrombotic complications of atherosclerosis. Raised levels of inflammatory mediators have been reported in subjects with atherosclerosis. Increased risk for CV events is associated with increased levels of cytokines, P-selectin and E-selectin, and acute phase reactants, such as a high sensitivity C-reactive protein and serum amyloid-A represent a risk for cardiovascular events. Elevation of some of these markers predicts the outcomes of patients with acute coronary syndromes and long-term outcomes. Therefore, the role of inflammation in the pathophysiology of arterial thromboembolic events has been elucidated.

However, little is known about the relationship between inflammation and venous thrombosis. Recently, inflammation has been accepted as a possible mechanism through which different risk factors trigger thrombus formation in veins. Patients with idiopathic DVT have long-term increased inflammatory markers. These findings favor the hypothesis that inflammation is a cause and not merely a consequence of acute DVT. Considerable progress in the understanding of the role of inflammation in cardiovascular disease has opened new possibilities for their management. Recently new drugs mediating the direct inhibition of inflammation were developed.

Recent findings indicate that inflammation represents the basic pathogenetic mechanism of arterial atherosclerotic and venous thromboembolic disease. Inflammation represents a common denominator of harmful effects of risk factors, which are involved in venous or arterial disease, particularly atherosclerosis, and deep or superficial venous thrombosis. However, till now the importance of inflammation in the pathogenesis of this disease was neglected and the treatment is mostly based on antithrombotic drugs and the elimination of risk factors. Recently, new drugs with anti-inflammatory effects on vessel walls are developing.

Therefore, the aim of this Special Issue should be: to collect the data on the involvement of inflammation in CV and VTE disease, the relationship between risk factors and inflammation, anti-inflammatory drugs in the prevention and treatment of these diseases.

Prof. Dr. Pavel Poredoš
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• atherosclerosis
• inflammation
• pathogenesis of venous thromboembolic disease
• anti-inflammatory treatment